Simplex Trading’s Gain Therapeutics GANX Stock Holding History

Simplex Trading’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.95K	Sell	4,100 -14,500	-78%	-$31.6K	﹤0.01%	7554
2025 Q4	$59.9K	Sell	18,600 -64,100	-78%	-$171K	﹤0.01%	5496
2025 Q3	$146K	Buy	+82,700	New	+$140K	﹤0.01%	5306
2025 Q2	–	Sell	-1,400	Closed	-$2K	–	8999
2025 Q1	$2K	Sell	1,400 -5,000	-78%	-$11.1K	﹤0.01%	7983
2024 Q4	$13K	Buy	+6,400	New	+$12.8K	﹤0.01%	6999
2024 Q2	–	Sell	-300	Closed	-$1K	–	9122
2024 Q1	$1K	Sell	300 -15,000	-98%	-$62.2K	﹤0.01%	8564
2023 Q4	$49K	Buy	15,300 +200	+1%	+$556	﹤0.01%	6094
2023 Q3	$49K	Sell	15,100 -28,100	-65%	-$107K	﹤0.01%	5820
2023 Q2	$193K	Sell	43,200 -2,800	-6%	-$13.7K	﹤0.01%	4330
2023 Q1	$221K	Buy	+46,000	New	+$188K	﹤0.01%	4203

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's GANX Position: Q1 2026 in Review

Simplex Trading reduced its Gain Therapeutics (GANX) stake by 72% in Q1 2026, selling an estimated $75.1K and leaving 13,439 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6533.

Simplex Trading first reported a position in GANX in Q3 2022 and has held it in 9 quarters since. The position peaked at $154K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Simplex Trading held 13,439 shares of Gain Therapeutics worth $26.1K as of Q1 2026.
Simplex Trading sold 34,507 Gain Therapeutics shares in Q1 2026, an estimated $75.1K.
Gain Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6533 holding.
Simplex Trading first reported a position in Gain Therapeutics in Q3 2022 and has held it in 9 quarters since.
Simplex Trading's Gain Therapeutics position peaked at $154K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.